OverviewSuggest Edit
Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
| Type | Public | |
| Founded | 2012 | |
| HQ | Redwood City, US | Map |
| Website | allakos.com |
Recent NewsAll News
- Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
- Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
- ROSEN, NATIONAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Allakos Inc. - ALLK
- HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed
Key People/Management at Allakos
Dan Janney
Chairman
Robert Alexander
Chief Executive Officer, Director
Robert Andreatta
Director
Mark Asbury
Chief Legal Officer, General Counsel
Paul Walker
Director
Steven P. James
Director
Allakos Office Locations
Allakos has an office in Redwood City
Redwood City, US (HQ)
975 Island Dr #201
Allakos Financials and Metrics
Allakos Revenue
| USD | |
|---|---|
Net income (Q2, 2020) | (39.3m) |
EBIT (Q2, 2020) | (40.4m) |
Market capitalization (17-Nov-2020) | 5.3b |
Closing stock price (17-Nov-2020) | 101.5 |
Cash (30-Jun-2020) | 153.9m |
EV | 5.2b |
Allakos's current market capitalization is $5.3 b.
Annual
Annual
Annual
Quarterly
| USD | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|
Net Income | (17.9m) | (29.0m) | (20.0m) | (39.0m) | (60.8m) | (27.8m) | (67.1m) |
Depreciation and Amortization | 119.0k | 183.0k | 357.0k | 732.0k | 393.0k | ||
Accounts Payable | (647.0k) | 915.0k | 1.3m | 874.0k | 1.7m | 3.1m | 3.7m |
Cash From Operating Activities | (17.4m) | (25.8m) | (13.3m) | (27.7m) | (43.9m) | (18.6m) | (43.7m) |
| USD | FY, 2016 |
|---|---|
Financial Leverage | -0.4 x |
Allakos Cybersecurity Score
Allakos Environment, Social & Governance (ESG) Ratings
Allakos Online and Social Media Presence
Allakos's Trends
Allakos News and Updates
October 26, 2020
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Management to host conference call and webcast today at 8:00 am ET --
August 10, 2020
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an …
March 12, 2020
ROSEN, NATIONAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Allakos Inc. - ALLK
NEW YORK, March 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is first to file a class action lawsuit on behalf of purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the "Class...
March 12, 2020
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed
SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims. Class...
January 18, 2020
ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. - ALLK
NEW YORK, Jan. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...
December 20, 2019
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud
SAN FRANCISCO, Dec. 19, 2019 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. The firm is investigating Allakos...
Allakos Blogs
November 09, 2020
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
Content Import
Mon, 11/09/2020 - 08:04
Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
November 9, 2020 at 8:01 AM EST
This release is a backfil…
November 02, 2020
Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
REDWOOD CITY, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020
October 29, 2020
Allakos Announces Pricing of Public Offering of Common Stock
Allakos Announces Pricing of Public Offering of Common Stock
Content Import
Wed, 10/28/2020 - 20:20
Allakos Announces Pricing of Public Offering of Common Stock
October 28, 2020 at 8:20 PM EDT
This release is a backfill from a News Wire
General
…
October 27, 2020
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
REDWOOD CITY, Calif. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020 .
October 21, 2020
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
Content Import
Wed, 10/21/2020 - 17:00
Allakos Announces Publication of Results fro…
June 03, 2020
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis -- -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Allakos Inc.
Allakos Frequently Asked Questions
When was Allakos founded?
Allakos was founded in 2012.
Who are Allakos key executives?
Allakos's key executives are Dan Janney, Robert Alexander and Robert Andreatta.
How many employees does Allakos have?
Allakos has 96 employees.
Who are Allakos competitors?
Competitors of Allakos include Quellis Biosciences, Nocion Therapeutics and Vyriad.
Where is Allakos headquarters?
Allakos headquarters is located at 975 Island Dr #201, Redwood City.
Where are Allakos offices?
Allakos has an office in Redwood City.
How many offices does Allakos have?
Allakos has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies